82. Medical Press Pre-Launch Feature Outline, Zyprexa MDL 1596, confidential subject to protection order ZY200187608. http://zyprexalitigationdocuments.com/per cent5Cdocuments per cent5CConfidentiality-Challenge per cent5CDocschallenged-in-10-3list per cent5C145-ZY200187608-7614.pdf
83. Drug Industry Document Archive [Internet]. [cited 2012 Mar 24]. Available from: http://dida.library.ucsf.edu/
84. Drug Industry Document Archive Search Results [Internet]. [cited 2012 Mar 24]. Available from: http://dida.library.ucsf. edu/ tid/anu38h10
85. Ibid.
86. Ross, J.S., K.P. Hill, D.S. Egilman, and H.M. Krumholz. 2008. Guest authorship and ghostwriting in publications related to rofecoxib: A case study of industry documents from rofecoxib litigation. Journal of the American Medical Association 299: 18001812.
87. POGO Letter to NIH on Ghostwriting Academics [Internet]. Project On Government Oversight. [cited 2012 Mar 24]. Available from: http://www.pogo.org/pogo-files/letters/publichealth/ ph-iis-20101129.html
88. http://www.nytimes.com/2010/11/30/business/30drug.html
89. http://pogoblog.typepad.com/pogo/gw-attachment-e.html
90. Lacasse JR, Leo J. Ghostwriting at Elite Academic Medical Centers in the United States. PLoS Med. 2010 Feb 2;7(2):e1000230.
91. Matheson A. How Industry Uses the ICMJE Guidelines to Manipulate Authorship And How They Should Be Revised. PLoS Med. 2011;8(8):e1001072.
92. Dyer O. Journal rejects article after objections from marketing department. BMJ. 2004 Jan 31;328(7434):244-b-244.
93. Fugh-Berman A, Alladin K, Chow J. Advertising in Medical Journals: Should Current Practices Change? PLoS Med. 2006 May 2;3(6):e130.
94. Becker A, Dorter F, Eckhardt K, Viniol A, Baum E, Kochen MM, et al. The association between a journal’s source of revenue and the drug recommendations made in the articles it publishes. CMAJ. 2011 Feb 28 Available from: http://www.cmaj.ca/content/early/2011/02/28/cmaj.100951
95. Smith R. Medical Journals Are an Extension of the Marketing Arm of Pharmaceutical Companies. PLoS Med. 2005 May 17;2(5):e138.
96. AUTH/2424/8/11 and AUTH/2425/8/11 General Practitioner v Boehringer Ingelheim and Lilly. Available from: http://www. pmcpa.org.uk/?q=node/998.
97. Handel AE, Patel SV, Pakpoor J, Ebers GC, Goldacre B, Ramagopalan SV. High reprint orders in medical journals and pharmaceutical industry funding: case-control study. BMJ. 2012 Jun 28;344(jun28 1):e4212-e4212.
98. Jefferson T, Di Pietrantonj C, Debalini MG, Rivetti A, Demicheli V. Relation of study quality, concordance, take home message, funding, and impact in studies of influenza vaccines: systematic review. BMJ. 2009 Feb 12;338(feb12_2):b354.
99. http://classic.the-scientist.com/blog/display/55679/
100. http://elsevier.com/wps/find/authored _newsitem.cws_home/ companynews05_01203
101. Bowman MA. The impact of drug company funding on the content of continuing medical education. Mobius: A Journal for Continuing Education Professionals in Health Sciences. 1986 Jan 1;6(1):66-9.
102. Bowman MA, Pearle DL. Changes in drug prescribing patterns related to commercial company funding of continuing medical education. Journal of Continuing Education in the Health Professions. 1988 Jan 1;8(1):13–20.
103. The Carlat Psychiatry Blog: PRMS [Internet]. [cited 2012 Mar 31]. Available from: http://carlatpsychiatry.blogspot.co.uk/ search/label/PRMS
104. Stephan Sahm, ‘Of mugs, meals and more: the intricate relations between physicians and the medical industry.,’ Medicine, health care, and philosophy (2011).
105. Avorn J, Choudhry NK. Funding for Medical Education: Maintaining a Healthy Separation From Industry. Circulation. 2010 May 25;121(20):2228-34.
106. L. Garattini et al., ‘Continuing Medical Education in six European countries: A comparative analysis,’ Health policy 94, no. 3 (2010): 246–254.
107. Eckardt VF. Complimentary journeys to the World Congress of Gastroenterology an inquiry of potential sponsors and beneficiaries. Z Gastroenterol. 2000 Jan;38(1):7-11.
108. http://www.pmlive.com/find_an_article/allarticles/categories/ General/2011/november_2011/features/cme_continuing_medic al_education_change
109. US Senate Committee on Finance. Committee Staff Report to the Chairman and Ranking Member: Use of Educational Grants by Pharmaceutical Manufacturers. Washington, DC: Government Printing Office; 2007.
110. Hensley S, Martinez B. To sell their drugs, companies increasingly rely on doctors. Wall St J (East Ed). 2005 Jul 15;A1,A2.
111. Tabas JA, Boscardin C, Jacobsen DM, Steinman MA, Volberding PA, Baron RB. Clinician Attitudes About Commercial Support of Continuing Medical Education: Results of a Detailed Survey. Arch Intern Med. 2011 May 9;171(9):840-6.
112. Amy T Wang et al., ‘Association between industry affiliation and position on cardiovascular risk with rosiglitazone: cross sectional systematic review,’ BMJ 340, no. 18 (March 18, 2010): c1344.
113. Rothman KJ, Evans S (2005) Extra scrutiny for industry funded trials. BMJ 331: 1350-1351
114. Wager E, Mhaskar R, Warburton S, Djulbegovic B (2010) JAMA Published Fewer Industry-Funded Studies after Introducing a Requirement for Independent Statistical Analysis. PLoS ONE 5(10): e13591. doi:10.1371/journal.pone.0013591
115. Chalmers TC, Frank CS, Reitman D. Minimizing the Three Stages of Publication Bias. JAMA. 1990 Mar 9;263(10):1392-5.
116. Samena Chaudhry et al., ‘Does declaration of competing interests affect readers’ perceptions? A randomised trial,’ BMJ 325, no. 7377 (December 14, 2002): 1391–1392. (below).
117. Reporting of Conflicts of Interest in Meta-analyses of Trials of Pharmacological Treatments. JAMA. 2011;305(10):1008–1017. doi: 10.1001/jama.2011.257
118. Loewenstein G, Sah S, Cain DM. The Unintended Consequences of Conflict of Interest Disclosure. JAMA. 2012 Feb 15;307(7):669-70.
119. Cain, D. M., Loewenstein, G., & Moore, D. A. (2005). The dirt on coming clean: perverse effects of disclosing conflicts of interest. Journal of Legal Issues, 34, 1e25.
120. Campbell EG, Weissman JS, Ehringhaus S et al. Institutional academic industry relationships. JAMA 2007;298:1779-86.
121. http://www.propublica.org/series/dollars-for-docs
122. http://www.propublica.org/article/doctors-dine-on-drugcompanies-dime
123. http://www.propublica.org/article/dollars-for-docs-sparkspolicy-rewrite-at-colorado-teaching-hospitals
124. http://www.propublica.org/article/medical-schools-plug-holesin-conflict-of-interest-policies
125. http://www.propublica.org/article/dollars-to-doctorsphysiciandisciplinary-records/single
126. http://www.propublica.org/article/drug-companies-reducepayments-to-doctors-as-scrutiny-mounts
127. http://www.propublica.org/article/piercing-the-veil-moredrugcompanies-reveal-payments-to-doctors
128. Carlowe J. Drug companies to declare all payments made to doctors from 2012. BMJ. 2010 Nov 5;341(nov051):c6290-c6290.
129. Tuffs A. Two doctors in Germany are convicted of taking bribes from drug company. BMJ. 2010 Nov 9;341(nov092):c6359-c6359.
130. http://www.fcaalert.com/2011/02/articles/dojhhs-releases-newstatistics-about-sealed-qui-tam-cases/
131. Sweet M. Experts criticise industry sponsorship of articles on health policy in Australian newspaper. BMJ. 2011 Oct 25;343(oct25 2):d6903-d6903.
132. http://www.pmcpa.org.uk/?q=node/499
133. http://www.propublica.org/documents/item/87376-heartrhythm-society
134. http://www.propublica.org/article/medical-groups-shy-aboutdetailing-industry-financial-support
135. JP Kassirer. On the Take: How Medicine’s Complicity with Big Business Can Endanger Your Health. 1st ed. Oxford University Press, USA; 2004.
136. http://www.eatright.org/corporatesponsors/.
137. JP Kassirer. On the Take: How Medicine’s Complicity with Big Business Can Endanger Your Health. 1st ed. Oxford University Press, USA; 2004, p105.
138. Choudhry NK, Stelfox HT, Detsky AS. Relationships between authors of clinical practice guidelines and the pharmaceutical industry. JAMA. 2002 Feb 6;287 (5):612-7.
1. Department of Justice, Office of Public Affairs. GlaxoSmithKline to Plead Guilty and Pay $3 Billion to Resolve Fraud Allegations and Failure to Report Safety Data. Monday, July 2, 2012.http://www.justice.gov/opa/pr/2012/July/12-civ842.html
2. Glaxo executives cited in case now lead Sanofi, Actelion. Bloomberg News, 3/7/12. http://www.businessweek.com/news/ 201207-03/glaxo-executives-cited-in-case-now-lead-sanofiactelion
3. Inpharm 4/7/12. GSK ruling: another failing, but will the industry learn? http://www.inpharm.com/news/173307/gskrulinganother-failing-will-industry-learn
4. Glaxo Agrees to Pay $3 Billion in Fraud Settlement. New York Times, July 2 2012. http://www.nytimes.com/2012/07/03/ business/glaxosmithkline-agrees-to-pay-3-billion-in-fraudsettlement.html
5. Level playing field push to continue despite setback 8 December 2011. Medicines Australia. http://medicinesaustralia. com. au/2011/12/08/level-playing-field-push-to-continue-despitesetback/
6. Drug companies to work with CCGs on care pathways and case finding under DH-backed scheme. Pulse, 28 May 2012, http://www.pulsetoday.co.uk/ newsarticle-content/-/article_ display_ list/14029608/drug-companies-to-work-with-ccgs-oncarepathways-and-case-finding-under-dh-backed-scheme.
7. Bosch X, Esfandiari B, McHenry L. Challenging Medical Ghostwriting in US Courts. PLoS Med. 2012 Jan 24;9(1): e1001163.
1. The citation here is, for obvious reasons, ‘personal communication’. The email from the academic continued: ‘From my perspective, I don’t think we should be anything but indignant!’